Eli Lilly (LLY)

In the face of the most aggressive antitrust environment in decades and the sweeping legislative changes of the 2025 "One Big Beautiful Bill Act" (OBBBA), the healthcare sector has not retreated from its consolidation ambitions. Instead, strategic buyers have evolved, trading the broad "mega-merger" attempts of the past for targeted,

As of March 18, 2026, Hims & Hers Health (NYSE: HIMS) has reclaimed its position as the primary protagonist in the direct-to-consumer (DTC) healthcare narrative. Following a turbulent start to the year characterized by regulatory uncertainty and legal skirmishes, the company’s stock staged a breathtaking 50%+ rally in the first two weeks of March. This [...]

Each of these companies could benefit from this high-growth market over time.

These companies are benefiting from a tidal wave of demand for new weight-loss drugs.

Today, March 17, 2026, selective tech gains helped lift the Nasdaq even as oil prices and geopolitical tensions stayed elevated.

What Happened? Shares of global pharmaceutical company Eli Lilly (NYSE:LLY) fell 6.3% in the afternoon session after investment bank HSBC downgraded the stoc...

You don't have to go all in to profit from AI.

The analyst’s new price target represents a potential downside of about 14% from the stock’s last closing price on Monday.

Eli Lilly's stock price is based on growth rates that might fall short.

HSBC downgrades Eli Lilly to reduce, citing pricing pressure, rising competition, and overestimated obesity drug market growth expectations.

Novo Nordisk recently announced promising trial results for one of its GLP-1 drugs in development.

Pfizer has reached a turning point.

Eli Lilly's stock is down this year, and its high valuation may be a big reason why.

Amidst a backdrop of mounting geopolitical tensions and sharp swings in the broader indices, pharmaceutical giant Merck & Co. (NYSE: MRK) officially trades ex-dividend today, March 16, 2026. Investors who held the stock prior to today’s session are now locked in to receive a quarterly payout of $0.85 per

The drama and uncertainty around Novo Nordisk and Hims & Hers Health might finally be ending.

Eli Lilly's Phase 3 results for Ebglyss in children with severe eczema, shows skin clearance and itch relief in trial patients.

Quality compounders are flywheels. Said differently, they’re businesses that generate heaps of profits and consistently reinvest them to produce even more pr...

This biotech firm develops therapies targeting cystic fibrosis, with shares up nearly 90% year-over-year as of the latest filing.

RAPT Therapeutics develops oral therapies for cancer and inflammation, with key drug candidates currently in clinical trials.